Clinical Trials Directory

Trials / Completed

CompletedNCT00681005

A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
178 (actual)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Backgrounds \& Aims: Proton-pump inhibitor (PPI) test has been proposed as a valuable tool in the diagnosis of gastroesophageal reflux disease (GERD) in Western populations. We assumed that a higher prevalence of poor metabolizers in Chinese population might affect the diagnostic accuracy of a PPI test. Methods: In this open-label, randomized trial, patients with symptoms suggestive of GERD were randomly assigned to receive a 2-week test with daily rabeprazole 40-mg or daily pantoprazole 80-mg after diagnostic endoscopy. Therapeutic response was assessed with a five-grade daily record. Genotypes of cytochrome P450 (CYP) 2C19 polymorphism were determined.

Detailed description

As described above

Conditions

Interventions

TypeNameDescription
DRUGrabeprazole20 mg bid for 14 days
DRUGpantoprazolepantoprazole 40 mg bid

Timeline

Start date
2006-04-01
Primary completion
2008-01-01
Completion
2008-01-01
First posted
2008-05-20
Last updated
2013-12-11

Source: ClinicalTrials.gov record NCT00681005. Inclusion in this directory is not an endorsement.

A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes (NCT00681005) · Clinical Trials Directory